Largest health care pharmaceutical companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 52 health care pharmaceutical companies ranked by revenue, at SAR 353.4B, ahead of Eli Lilly (SAR 244.5B) and Merck & Co (SAR 243.9B). Figures as of 20 Nov 2026, 08:57 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 52
- First
- Johnson & JohnsonSAR 353.4B
- Median
- SAR 12B
- Combined market value
- SAR 18.62T
- Countries
- 10
- Not ranked
- 9no revenue on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | SAR 353.4B | SAR 2.41T | SAR 1,002.23 | 2.04% down | 34% up | ||
| 2 | Eli LillyLLY · Health Care | SAR 244.5B | SAR 4.52T | SAR 5,069.00 | 2.29% down | 33% up | ||
| 3 | Merck & CoMRK · Health Care | SAR 243.9B | SAR 1.23T | SAR 498.26 | 3.61% down | 45% up | ||
| 4 | PfizerPFE · Health Care | SAR 234.8B | SAR 588.9B | SAR 103.32 | 1.85% down | 15% up | ||
| 5 | AbbVieABBV · Health Care | SAR 229.5B | SAR 1.88T | SAR 1,063.76 | 0.86% down | 25% up | ||
| 6 | AstraZenecaAZN · Health Care | SAR 220.4B | SAR 1.02T | SAR 658.09 | 1.87% down | 1% up | ||
| 7 | NovartisNVS · Health Care | SAR 204.6B | SAR 1.07T | SAR 567.33 | 2.57% down | 25% up | ||
| 8 | SanofiSNY · Health Care | SAR 181.6B | SAR 414.9B | SAR 172.80 | 2.25% down | 4% down | ||
| 9 | Bristol-Myers SquibbBMY · Health Care | SAR 180.8B | SAR 447.4B | SAR 218.87 | 2.05% down | 30% up | ||
| 10 | Novo NordiskNVO · Health Care | SAR 172.1B | SAR 642.7B | SAR 145.83 | 1.42% down | 17% down | ||
| 11 | Abbott LaboratoriesABT · Health Care | SAR 166.3B | SAR 674.9B | SAR 389.69 | 0.58% down | 16% down | ||
| 12 | GSKGSK · Health Care | SAR 162.7B | SAR 359.6B | SAR 179.41 | 1.56% down | 5% up | ||
| 13 | Takeda PharmaceuticalTAK · Health Care | SAR 105.9B | SAR 256.6B | SAR 80.32 | 0.66% up | 51% up | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | SAR 64.7B | SAR 168.7B | SAR 144.59 | 8.74% down | 74% up | ||
| 15 | Regeneron PharmaceuticalsREGN · Health Care | SAR 53.8B | SAR 358.4B | SAR 3,464.09 | 2.35% down | 28% up | ||
| 16 | ViatrisVTRS · Health Care | SAR 53.6B | SAR 85.5B | SAR 74.58 | 1.97% down | 99% up | ||
| 17 | Vertex PharmaceuticalsVRTX · Health Care | SAR 45B | SAR 495.3B | SAR 1,953.36 | 2.94% down | 27% up | ||
| 18 | ZoetisZTS · Health Care | SAR 35.5B | SAR 123.2B | SAR 303.10 | 5.59% down | 26% down | ||
| 19 | GrifolsGRFS · Health Care | SAR 31.3B | SAR 20.9B | SAR 30.76 | 3.19% down | 0% up | ||
| 20 | BeOne MedicinesONC · Health Care | SAR 20B | SAR 171.3B | SAR 1,499.55 | 0.97% down | 16% up | ||
| 21 | Elanco Animal HealthELAN · Health Care | SAR 17.7B | SAR 49.3B | SAR 98.63 | 1.54% down | 26% up | ||
| 22 | Jazz PharmaceuticalsJAZZ · Health Care | SAR 16B | SAR 56.9B | SAR 887.09 | 4.57% down | 41% up | ||
| 23 | GenmabGMAB · Health Care | SAR 14B | SAR 118.8B | SAR 192.65 | 0.75% up | 70% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | SAR 13.9B | SAR 74.3B | SAR 554.58 | 1.06% down | 66% down | ||
| 25 | Dr. Reddy's LaboratoriesRDY · Health Care | SAR 13.4B | SAR 46.4B | SAR 55.64 | 1.00% down | 8% up | ||
| 26 | BioMarin PharmaceuticalBMRN · Health Care | SAR 12.1B | SAR 44.6B | SAR 230.43 | 0.02% down | 17% up | ||
| 27 | United TherapeuticsUTHR · Health Care | SAR 11.9B | SAR 89.3B | SAR 2,097.58 | 3.16% down | 22% up | ||
| 28 | Amneal PharmaceuticalsAMRX · Health Care | SAR 11.3B | SAR 28B | SAR 80.25 | 2.24% down | 90% up | ||
| 29 | Royalty PharmaRPRX · Health Care | SAR 8.9B | SAR 146.1B | SAR 254.07 | 1.38% down | 79% up | ||
| 30 | PTC TherapeuticsPTCT · Health Care | SAR 6.5B | SAR 18.3B | SAR 218.82 | 3.16% down | 21% down | ||
| 31 | AlkermesALKS · Health Care | SAR 5.5B | SAR 29.1B | SAR 173.25 | 1.43% down | 66% up | ||
| 32 | Legend BiotechLEGN · Health Care | SAR 3.9B | SAR 11.7B | SAR 60.40 | 0.92% down | 41% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | SAR 3.6B | SAR 34.6B | SAR 1,488.45 | 0.34% down | 27% down | ||
| 34 | Ionis PharmaceuticalsIONS · Health Care | SAR 3.5B | SAR 17B | SAR 102.12 | 0.62% down | 63% down | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | SAR 3.1B | SAR 23.2B | SAR 163.76 | 1.25% up | 13% up | ||
| 36 | Ascendis PharmaASND · Health Care | SAR 3B | SAR 63B | SAR 960.29 | 5.32% down | 29% up | ||
| 37 | Corcept TherapeuticsCORT · Health Care | SAR 2.9B | SAR 26.7B | SAR 243.79 | 4.15% down | 10% down | ||
| 38 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | SAR 2.5B | SAR 27.6B | SAR 350.92 | 1.59% down | 129% up | ||
| 39 | Axsome TherapeuticsAXSM · Health Care | SAR 2.4B | SAR 26.8B | SAR 509.03 | 1.25% up | 6% down | ||
| 40 | TG TherapeuticsTGTX · Health Care | SAR 2.3B | SAR 36.8B | SAR 243.41 | 1.88% down | 117% up | ||
| 41 | InsmedINSM · Health Care | SAR 2.3B | SAR 118.9B | SAR 541.97 | 20.58% up | 40% down | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | SAR 2B | SAR 23.4B | SAR 358.32 | 3.27% up | 34% up | ||
| 43 | BridgeBio PharmaBBIO · Health Care | SAR 1.9B | SAR 57.1B | SAR 293.31 | 0.22% up | 21% up | ||
| 44 | Travere TherapeuticsTVTX · Health Care | SAR 1.8B | SAR 17.4B | SAR 181.21 | 3.86% down | 45% up | ||
| 45 | Ligand PharmaceuticalsLGND · Health Care | SAR 1B | SAR 21.5B | SAR 1,076.51 | 3.94% down | 50% up | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | SAR 711.9M | SAR 30.4B | SAR 438.20 | 1.88% down | 18% up | ||
| 47 | CytokineticsCYTK · Health Care | SAR 330.3M | SAR 26.9B | SAR 193.06 | 0.27% up | 19% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | SAR 172.6M | SAR 30.4B | SAR 465.29 | 2.47% down | 51% up | ||
| 49 | Roivant SciencesROIV · Health Care | SAR 31M | SAR 105.9B | SAR 146.17 | 0.59% up | 91% up | ||
| 50 | Dianthus TherapeuticsDNTH · Health Care | SAR 7.6M | SAR 17.9B | SAR 318.26 | 1.01% up | 108% up | ||
| 51 | Spyre TherapeuticsSYRE · Health Care | SAR 0 | SAR 34.8B | SAR 366.28 | 3.77% down | 332% up | ||
| 52 | Praxis Precision MedicinesPRAX · Health Care | SAR 0 | SAR 32.6B | SAR 1,166.40 | 1.87% up | 86% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7517 SAR). 9 companies have no revenue on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies rank first by revenue?
Johnson & Johnson (SAR 353.4B), Eli Lilly (SAR 244.5B) and Merck & Co (SAR 243.9B) are the top three of the 52 health care pharmaceutical companies ranked by revenue as of 20 Nov 2026, 08:57 UTC.
How many health care pharmaceutical companies are in this ranking?
52 are ranked by revenue. 9 more have no revenue on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 52 health care pharmaceutical companies ranked by revenue have a combined market value of SAR 18.62T as of 20 Nov 2026, 08:57 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest health care pharmaceutical companies by revenue”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.